[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100115391":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":33,"centralContacts":10,"locations":38,"responsibleParty":50,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":75,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,12,15,18,21,24,27,30],{"label":9,"type":10,"description":11,"interventionNames":10},"A:",null,"70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and\u002For radiotherapy just recently (up to 6 months after completion of therapy)",{"label":13,"type":10,"description":14,"interventionNames":10},"B","70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and\u002For radiotherapy",{"label":16,"type":10,"description":17,"interventionNames":10},"C","70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and\u002For radiotherapy",{"label":19,"type":10,"description":20,"interventionNames":10},"D","70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy",{"label":22,"type":10,"description":23,"interventionNames":10},"E","70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy",{"label":25,"type":10,"description":26,"interventionNames":10},"F","70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy",{"label":28,"type":10,"description":29,"interventionNames":10},"G","70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy",{"label":31,"type":10,"description":32,"interventionNames":10},"H","70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy",[34],{"name":35,"affiliation":36,"role":37},"Simona Borstnar, MD, PhD","Institute of Oncology Ljubljana","PRINCIPAL_INVESTIGATOR",[39],{"facility":40,"status":10,"city":41,"state":10,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":10},"Research Site","Ljubljana","Slovenia","SI",{"type":45,"coordinates":46},"Point",[47,48],14.50513,46.05108,{"lat":48,"lon":47},{"type":10,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":51,"oldOrganization":52},"Meta Jeras, Mr Ph, Regulatory and Medical Affairs Manager","AstraZeneca UK Limited, Branch Office in Slovenia","100115391","an-open-label-non-interventional-evaluation-of-the-effect-of-adjuvant-hormonal-treatment-of-postmenopausal-women-wih-early-breast-cancer-with-aromatase-inhibitors-on-bone-mineral-density-and-bone-fracture-rate-in-daily-practice-100115391",false,"NCT00767585","An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice","Inclusion Criteria:\n\n* Women aged 55-65 years, diagnosed with invasive early breast cancer: - Surgery, chemo- and\u002For radiotherapy concluded less than 6 months ago\n* Women with hormone-independent breast cancer: - Surgery, chemo- and\u002For radiotherapy concluded before 24-36 months or 54-66 months\n* Women with hormone-dependent breast cancer:- Adjuvant therapy with tamoxifen initiated before 24-36 and 54-66 months or - Adjuvant therapy with aromatase inhibitor initiated before 24-36 and 54-66 months or - Switch from tamoxifen to aromatase inhibitor initiated before 24-36 months\n\nExclusion Criteria:\n\n* Women receiving active treatment for osteoporosis\n* Women with any evidence of breast cancer recurrence","FEMALE","55 Years","65 Years",{"count":63,"type":64},560,"ESTIMATED","OBSERVATIONAL","The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.",[68,69],"Breast Cancer","Osteoporosis",[71,72,73,74],"breast cancer","aromatase inhibitors","bone mineral density","osteoporosis","COMPLETED","2009-07-02",{"date":78,"type":64},"2009-07-03",{"date":80,"type":10},"2008-08",{"date":82,"type":83},"2009-06","ACTUAL",{"name":5,"class":6},1]